Business
Transgene Appoints Seasoned Industry Executive Emmanuelle Quilès to Board of Directors as Independent Director
Strasbourg, France, July 9, 2025, 5:45 p.m. CET — Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced the appointment of Emmanuelle Quilès as an independent Director to its Board of Directors. She succeeds Philippe Archinard, who is retiring from the Board. Emmanuelle Quilès brings more than 25 years of experience in strategic leadership roles across the global pharmaceutical industry. Until recentl
About this update from Transgene Sa
[{"type":"image","alt":"Transgene S.A.","displaySize":"","headline":null,"caption":"Transgene S.A.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":87,"url":"https://media.zenfs.com/en/globenewswire.com/5e2bda2eb0d0beeae1e11d3a6a53975d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Mk1nX91jR7AbltXY2XQlzQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5e2bda2eb0d0beeae1e11d3a6a53975d","width":300,"height":87}},"lazy":false},{"type":"text","content":"Strasbourg, France, July 9, 2025, 5:45 p.m. CET — Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced the appointment of Emmanuelle Quilès as an independent Director to its Board of Directors. She succeeds Philippe Archinard, who is retiring from the Board.","length":360,"tagName":"p"},{"type":"text","content":"Emmanuelle Quilès brings more than 25 years of experience in strategic leadership roles across the global pharmaceutical industry. Until recently, Emmanuelle Quilès served as Worldwide Vice President for Cardiovascular, Metabolism and Pulmonary Hypertension at Janssen Global Commercial Strategy Organization (Johnson & Johnson).","length":333,"tagName":"p"},{"type":"text","content":"The Board of Directors voted to appoint Emmanuelle Quilès to serve the remainder of Philippe Archinard’s term, that is until the 2026 Annual Shareholders’ Meeting. This appointment is effective from July 9, 2025.","length":212,"tagName":"p"},{"type":"text","content":"Dr. Alessandro Riva, MD, Chairman and CEO of Transgene, commented: “On behalf of Transgene’s entire Board and leadership team, I would like to extend our warmest thanks to Philippe for his long-term leadership and commitment to Transgene that have been instrumental to continuing our mission of improving patients’ lives.At the same time, I would like to welcome Emmanuelle Quilès as the newest member to our Board. I believe Transgene will benefit greatly from her longstanding global pharmaceutical industry experience and strategic expertise, shaped by her many years in key operational and leadership roles across the sector.”","length":636,"tagName":"p"},{"type":"text","content":"Emmanuelle Quilès - Biography Emmanuelle Quilès is a seasoned pharmaceutical industry ex...